Your search

In authors or contributors
Resource language
  • Individuals with autism spectrum disorder (ASD) often have co-morbid anxiety and depression. Alexithymia and emotion regulation difficulties are commonly seen in individuals with ASD and in mood disorders. We hypothesized that alexithymia and emotional regulation would mediate the relationship between autistic features and anxiety/depression symptom severity. We collected data about emotional regulation, alexithymia, autistic symptoms and depression/anxiety in a sample of 64 young adults with ASD. We constructed two serial multiple mediator models, using autistic features as the independent variable and anxiety/depression symptoms as outcome variables. The serial relationship between alexithymia and emotional regulation mediated associations between autistic features and depression and anxiety, separately. The findings suggest that targeting alexithymia may benefit therapies designed to alleviate mood disorders in ASD.

  • Background: Stimulant use disorder (StUD) and attention-deficit/hyperactivity disorder (ADHD) frequently co-occur. This comorbidity complicates treatment and worsens clinical outcomes. Despite the high prevalence, shared vulnerability and clinical relevance of this comorbidity, evidence on effective pharmacotherapies among individuals with this dual diagnosis remains limited. Materials and methods: This systematic review protocol is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement and will include randomized controlled trials involving adults with comorbid StUD (cocaine, amphetamines, or methamphetamines) and ADHD. The following databases will be searched: PubMed, Embase, Scopus, and Web of Science. Covidence will be used to support independent screening and data extraction. Two reviewers will independently screen studies (title/abstract and full text). One author will extract data, which will be independently verified by a second reviewer. Quality assessment of included articles will be assessed using the Cochrane Risk of Bias instrument, and certainty of the evidence for each outcome will be assessed using Grading of Recommendations, Assessment, Development and Evaluations (GRADE) methodology. Primary outcomes include duration of continuous abstinence, odds of stimulant-negative urine samples, ADHD symptom changes, and medication adverse events. Where feasible, meta-analyses will be conducted using random-effects models. Significance and dissemination: This review will synthesize existing evidence on the efficacy of pharmacotherapies (stimulants and non-stimulants) for individuals with co-occurring StUD and ADHD. The results of this study will likely inform clinical practice by evaluating outcomes such as reduction in stimulant use and abstinence, and improvement in ADHD symptoms. Findings will be disseminated through peer-reviewed publication and presentations to reach both clinical and academic audiences. Systematic review registration: PROSPERO, CRD420250655356. Copyright © 2025 Oliva, Pulido-Saavedra, Paredes-Naveda, Forselius, Potenza, Jegede and Angarita.

  • Sleep disturbances are prevalent in substance use disorders (SUDs). Objective (e.g., polysomnography) and subjective (e.g., Pittsburgh sleep quality index [PSQI]) assessments are commonly used, with polysomnography enabling sleep architecture analysis and diagnosis of sleep disorders, but its use limited by logistical constraints. Actigraphy offers a feasible alternative for longitudinal and naturalistic assessment. We aimed to synthesize actigraphy-based sleep outcomes in individuals with SUDs and compare them with subjective sleep measures. We conducted a meta-analysis (PROSPERO: CRD420251072028), searching 8 databases by March, 2026. Studies included adults with SUDs reporting actigraphy-based parameters and/or subjective sleep outcomes. Nine studies (n = 1366) met inclusion criteria. Actigraphy showed reduced total sleep time in alcohol use disorder (AUD) (mean difference [MD] = −44.67; 95%CI: −56.10 to −33.24) and opioid use disorder (MD = −40.00, 95%CI = −72.08 to −7.92), and increased wake after sleep onset in nicotine use disorder (MD = 6.60; 95%CI: 2.41−10.80). Subjective data indicated poorer sleep quality in AUD (PSQI MD = 4.37; 95%CI: 1.28−7.47). Available evidence suggests consistent objective and subjective sleep disturbances in AUD and general concordance between actigraphy- and polysomnography-derived sleep parameters. Actigraphy appears to be a feasible objective tool for sleep assessment in SUDs, though additional studies across diverse substances are needed. © 2026

Last update from database: 5/15/26, 4:15 PM (UTC)

Explore

Resource type

Resource language